Breaking news

Cyprus Nears US Visa Waiver Program As Refusal Rate Drops Below 3%

Cyprus has achieved a significant milestone in its efforts to join the US Visa Waiver Program, with the 2024 visa refusal rate for Cypriot citizens reported at just 2.16%. This figure, announced by the US Department of State, is well below the program’s required threshold of 3%, marking a crucial step toward visa-free travel for Cypriots.

Progress Towards Inclusion

Deputy Minister to the President, Irene Piki, highlighted the importance of this development, stating that Cyprus has met a “key prerequisite” for its inclusion in the program. She credited the progress to successful technical consultations between Cyprus and the United States over the past year.

Piki reaffirmed the government’s commitment to securing Cyprus’ inclusion in the program by 2025, allowing Cypriots to travel to the US for tourism and business without the need for a visa.

Support from US Officials

US Ambassador to Cyprus, Julie Fisher, also acknowledged the milestone, describing it as a significant step forward. She expressed optimism that Cypriots would soon enjoy the benefits of visa-free travel to the US.

What’s Next?

The Cypriot government plans to continue its focused efforts to meet all remaining requirements, ensuring the process stays on track. This achievement underscores the growing cooperation between Cyprus and the US, paving the way for stronger ties and easier travel.

As Cyprus moves closer to this goal, the prospect of visa-free access to the US represents an important development for both business and leisure travellers.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

The Future Forbes Realty Global Properties
eCredo
Uol
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter